Drug Type Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals |
Synonyms 212Pb alpha targeted therapy (Viewpoint Molecular Targeting), 212PbVMT01, 212PbVMTalfaNET + [4] |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationFast Track (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroendocrine neoplasm of gastrointestinal tract | Phase 2 | US | 27 Jun 2024 | |
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 2 | US | 27 Jun 2024 | |
Carcinoid Tumor | Phase 2 | US | 27 Sep 2023 | |
Gastrointestinal Neoplasms | Phase 2 | US | 27 Sep 2023 | |
Neuroendocrine Carcinoma | Phase 2 | US | 27 Sep 2023 | |
Neuroendocrine neoplasm of lung | Phase 2 | US | 27 Sep 2023 | |
Pancreatic Cancer | Phase 2 | US | 27 Sep 2023 | |
Pheochromocytoma | Phase 2 | US | 27 Sep 2023 | |
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 2 | US | 27 Sep 2023 | |
Melanoma, Cutaneous Malignant | Phase 2 | US | 15 Dec 2022 |